VC-backed Travecta taps Hicks as chief business officer
Travecta Therapeutics, an emerging biotech company, has appointed Douglas C. Hicks as chief business officer. Previously, Hicks worked at iBio Inc where he served as senior vice president of business development and strategy. Based in Philadelphia and Singapore, Travecta is backed by TKS1, a healthcare and life science-focused venture capital fund formed by the partnership between SPRIM Ventures and Tikehau Capital.
13 September 2018•3 mins read
